Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA) Expands By 30.7%

ADMA Biologics, Inc. (NASDAQ:ADMA) was the recipient of a significant growth in short interest in September. As of September 15th, there was short interest totalling 12,420,000 shares, a growth of 30.7% from the August 31st total of 9,500,000 shares. Based on an average daily volume of 4,760,000 shares, the days-to-cover ratio is currently 2.6 days.

Insider Activity

In other news, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $17.69, for a total transaction of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares of the company’s stock, valued at $36,436,552.94. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, Director Lawrence P. Guiheen sold 9,000 shares of ADMA Biologics stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now directly owns 153,941 shares of the company’s stock, valued at $2,843,290.27. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Adam S. Grossman sold 236,889 shares of ADMA Biologics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $17.69, for a total value of $4,190,566.41. Following the sale, the chief executive officer now directly owns 2,059,726 shares in the company, valued at $36,436,552.94. The disclosure for this sale can be found here. Over the last three months, insiders have sold 466,900 shares of company stock valued at $8,224,121. 3.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On ADMA Biologics

Hedge funds have recently added to or reduced their stakes in the business. LSV Asset Management bought a new stake in ADMA Biologics in the first quarter worth approximately $1,028,000. Seven Eight Capital LP bought a new stake in ADMA Biologics in the second quarter worth approximately $1,992,000. BNP Paribas Financial Markets increased its holdings in shares of ADMA Biologics by 152.2% during the first quarter. BNP Paribas Financial Markets now owns 732,920 shares of the biotechnology company’s stock valued at $4,837,000 after acquiring an additional 442,315 shares in the last quarter. Alberta Investment Management Corp increased its holdings in shares of ADMA Biologics by 32.4% during the fourth quarter. Alberta Investment Management Corp now owns 460,774 shares of the biotechnology company’s stock valued at $2,083,000 after acquiring an additional 112,831 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its holdings in shares of ADMA Biologics by 90.7% during the first quarter. Russell Investments Group Ltd. now owns 1,169,207 shares of the biotechnology company’s stock valued at $7,717,000 after acquiring an additional 556,175 shares in the last quarter. 75.68% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research firms recently commented on ADMA. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $20.00 price objective on shares of ADMA Biologics in a research note on Friday, September 20th. Mizuho lifted their price objective on ADMA Biologics from $12.00 to $14.00 and gave the stock a “buy” rating in a research note on Thursday, June 20th. Finally, HC Wainwright lifted their price objective on ADMA Biologics from $10.00 to $18.00 and gave the stock a “buy” rating in a research note on Monday, August 12th. One research analyst has rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company currently has an average rating of “Buy” and an average price target of $15.50.

ADMA Biologics Trading Down 0.3 %

Shares of ADMA stock opened at $19.39 on Friday. The company has a market cap of $4.49 billion, a P/E ratio of -969.25 and a beta of 0.61. The stock has a 50 day simple moving average of $16.39 and a two-hundred day simple moving average of $11.39. The company has a debt-to-equity ratio of 0.74, a quick ratio of 2.80 and a current ratio of 6.87. ADMA Biologics has a fifty-two week low of $3.06 and a fifty-two week high of $20.16.

ADMA Biologics (NASDAQ:ADMA) last issued its earnings results on Thursday, August 8th. The biotechnology company reported $0.13 earnings per share for the quarter, topping analysts’ consensus estimates of $0.08 by $0.05. The business had revenue of $107.20 million during the quarter, compared to the consensus estimate of $86.44 million. ADMA Biologics had a return on equity of 38.79% and a net margin of 10.53%. The firm’s revenue for the quarter was up 78.4% on a year-over-year basis. During the same period in the previous year, the company posted ($0.02) earnings per share. Research analysts forecast that ADMA Biologics will post 0.49 earnings per share for the current year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.